FDA approves drug-coated balloon catheter Lutonix; Researchers implant world's tiniest pacemaker;

@FierceMedDev: Researchers implant brain-controlled prosthetic arm with sensation. Story | Follow @FierceMedDev

@VarunSaxena2: Hillary Clinton hedges on the device tax, says nation must weigh pros and cons. More | Follow @VarunSaxena2

@EmilyWFierce: $MDT sans José? Release | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in cancer cells. Article | Follow @MichaelGFierce

> FDA approved C.R. Bard's ($BCR) Lutonix 035 Drug Coated Balloon (DCB) Catheter for percutaneous transluminal angioplasty (PTA) for treatment of de novo or restenotic lesions. It is the first approved by the agency to treat femoropopliteal occlusive disease. More

> Cardiologists at Baylor Jack and Jane Hamilton Heart and Vascular Hospital in Dallas, TX ,have implanted an investigational cardiac pacemaker the size of a large pill; that's about one-tenth the size of a conventional pacemaker. The device is Medtronic's ($MDT) Micra Transcatheter Pacing System and the surgery is part of a trial for the device. Release

> Masimo ($MASI) has received a CE mark for use of its Radical-7 Pulse CO-Oximeters in newborn screening for congenital heart disease. Release

> Materialise's 3D printed hearts, used for pre-operative surgical planning, have been classified as Class I medical devices by FDA. More

Biotech News

@FierceBiotech: EuroBiotech Report: New U.K. biotech bags £15.5M, Forbion plans €200M fund, Serono strikes oncology deal. Report | Follow @FierceBiotech

@JohnCFierce: Regado's CEO steps down as the biotech limps forward. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. More | Follow @DamianFierce

@EmilyMFierce: At Phila. conference, how a hospital successfully treated Ebola. Story via Philly.com | Follow @EmilyMFierce

> Prosensa heads to the FDA with its once-failed DMD treatment. Story

> Isis rolls into Phase III with an orphan drug as it waits on Biogen. More

> Novartis to shed three division heads in midst of Glaxo, Lilly deal prep. Chutes & Ladders

Pharma News

@FiercePharma: Tops in FierceVaccines Thurs: Takeda appoints new vaccine development head as Novartis' Oswald heads for the door. Story | Follow @FiercePharma

@CarlyHFierce: Favorite PR of the morning so far: "The holiday stress lurking beneath the gingerbread." | Follow @CarlyHFierce

> PhRMA renews legal battle over big hospital discounts for orphan drugs. News

> Bristol-Myers, Otsuka ask judge to nix Abilify kickback suit. Story

> Novartis employee pleads guilty to bribery in Poland. Article

Suggested Articles

Qiagen launched a one-stop shop compiling publicly available genomic data, scientific literature and phenotypic information on potential superbugs.

Adaptive Biotechnologies is planning a $200 million IPO to help power its sequencing tests aimed at the body’s immune system and related therapies.

Abbott’s new diabetes test provides A1c results in three minutes, allowing clinicians to develop care plans within a single office visit.